+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
ID07098351

Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets for Moderate-to-Severe Itching in Peritoneal Dialysis Patients

Led by Guangdong Provincial People's Hospital · Updated on 2026-09-14

93

Participants Needed

1

Research Sites

23 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of nalfurafine hydrochloride orally disintegrating tablets to treat moderate-to-severe itching pruritus in patients undergoing peritoneal dialysis. This multicenter, prospective, single-arm clinical trial aims to improve quality of life by reducing itching, which significantly impacts patients on peritoneal dialysis. The study plans to enroll 93 patients aged 18 to 85 years who have been on peritoneal dialysis for at least three months and have moderate to severe pruritus based on specific scoring criteria. The study consists of three phases a screening period lasting 1 to 2 weeks, a 4-week treatment period, and a 1-week follow-up. During treatment, participants start with 2.5 micrograms of nalfurafine hydrochloride once daily after dinner or before bedtime for two weeks. Depending on symptom improvement measured by a visual scale, the dose may remain the same or increase to 5 micrograms daily for the next two weeks. The follow-up period evaluates pruritus improvement and safety. The treatment is monitored using standardized scales for itching severity, quality of life, and sleep quality, along with vital signs, electrocardiograms, and lab tests. Participants will record itching severity twice daily during screening and treatment. Researchers will assess changes in the visual analog scale VAS scores, itch severity scores, quality of life, sleep quality, and dose adjustments. Safety is closely monitored through laboratory tests and adverse event tracking. The total participation spans approximately 6 to 7 weeks. The primary outcome is the change in itching severity from baseline to week 4, with secondary outcomes including quality of life and sleep improvements, and safety evaluations.

CONDITIONS

Brief Title

Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis

Research Team

X

Xueqing Yu, Ph.D

Z

Zhiming Ye

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here